<DOC>
	<DOCNO>NCT02367872</DOCNO>
	<brief_summary>The purpose study examine effect renal hepatic impairment TAK-272 pharmacokinetics single oral administration TAK-272 patient renal hepatic impairment .</brief_summary>
	<brief_title>Phase I Open-label Study Evaluate Pharmacokinetics TAK-272 Patients With Renal Hepatic Impairment</brief_title>
	<detailed_description>This study phase I , open-label , parallel-group , comparative study evaluate effect renal hepatic impairment pharmacokinetics TAK-272 single oral administration TAK-272 patient renal hepatic impairment compare participant normal renal hepatic function .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>&lt; All participant &gt; 1 . Judged investigator subinvestigator capable understanding study comply requirement 2 . Signed date informed consent document study procedure perform 3 . Of either sex , age ≥ 20 year ≤ 85 year time consent 4 . Weight ≥ 45 kg male ≥ 40 kg female BMI &lt; 35.0 kg/m2 screening time preliminary examination 5 . Agree use appropriate contraception time consent 12 week investigational product administration male , currently receive contraceptive treatment , female partner capable become pregnant 6 . Agree use appropriate contraception time consent 1 month completion study female , capable become pregnant , male partner receive contraceptive treatment &lt; Participants normal renal hepatic function &gt; 7. eGFR ≥ 90 mL/min/1.73 m2 screen 8 . Based individual 's medical history , clinical laboratory value , physical examination finding , investigator subinvestigator judge individual good health ( present , hypertension , type 2 diabetes , hypercholesteremia dyslipidemia control ) 9 . Within ± 10 year mean age ± 20 % mean weight 24 participant renal impairment 12 participant hepatic impairment administer investigational product &lt; Participants renal impairment &gt; 10 . Covered follow category : Participants mild renal impairment : eGFR ≥ 60 mL/min/1.73 m2 &lt; 90 mL/min/1.73 m2 screen Participants moderate renal impairment : eGFR ≥ 30 mL/min/1.73 m2 &lt; 60 mL/min/1.73 m2 screen Participants severe renal impairment : eGFR &lt; 30 mL/min/1.73 m2 screen Hemodialysis participant : Participants endstage renal failure little urine output undergo hemodialysis 3 time weekly 11 . For nonhemodialysis participant , difference ≤ 30 % eGFR obtain 3 month 7 day screen eGFR screening . &lt; Participants hepatic impairment &gt; 12 . In observation screen period , diagnose hepatic impairment correspond follow ChildPugh class : Mild hepatic impairment : ChildPugh class A Moderate hepatic impairment : ChildPugh class 13 . Diagnosed investigator subinvestigator hepatic impairment remain stable 3 month screen . &lt; All participant &gt; 1 . Received another investigational product within 16 week ( 112 day ) administration investigational product study 2 . Previously receive TAK272 study 3 . Employed medical institution conducting study , relative someone employ , dependent ( e.g. , spouse , parent , child , sibling ) employee medical institution involve conducting study , individual may coerce consent participate study 4 . History cancer . Does include individual remission least 1 year start screen judge investigator subinvestigator recurrence study 5 . Hypersensitivity allergy TAK272 renin inhibitor 6 . Drug abuse ( define illicit drug use ) within 1 year screen clinic visit , history alcoholism , unwilling abstain alcohol drug use study 7 . Positive urine drug test screening ( include test alcohol ) individual undergo dialysis 8 . Use prohibit concomitant drug food ( section 7.3 ) period concomitant use prohibit , need use prohibit concomitant drug food study 9 . Previously undergone kidney liver transplantation 10 . Difficulty collect blood peripheral vein 11 . Collection ≥ 800 mL whole blood within 52 week ( 364 day ) start investigational product administration 12 . Collection ≥ 200 mL whole blood within 4 week ( 28 day ) investigational product administration ≥ 400 mL within 12 week ( 84 day ) males 16 week ( 112 day ) females 13 . Collection blood component 2 week ( 14 day ) start investigational product administration 14 . Myocardial infarction coronary revascularization within 6 month screen 15 . Abdominal surgery ( exclude laparoscopic cholecystectomy appendectomy without complication ) chest nonperipheral vascular surgery within 6 month screen 16 . Acute disease ( e.g. , renal urinary tract disease ) within 30 day screen 17 . Clinically significant ECG abnormality see screen period preliminary examination 18 . Clinically significant hyperkalemia 19 . Pregnant lactate female prior providing inform consent plan become pregnant study within 1 month completion , plan donate egg study 20 . Male plan donate sperm study within 12 week completion 21 . Judged investigator subinvestigator unlikely comply study protocol otherwise judge unsuitable study participation &lt; Participants normal renal hepatic function &gt; 22 . Poorly control clinically significant disease , infection , abnormality liver , kidney , nervous system , cardiovascular system , blood , lung , metabolism , gastrointestinal tract , urinary tract ; endocrine disorder ; immune disorder could affect study participation study result . 23 . Clinical laboratory result screen suggestive clinically significant underlying disease control hypertension , type 2 diabetes , hypercholesteremia , dyslipidemia 24 . Systolic blood pressure &lt; 80 mmHg screening , preliminary examination , examination administration investigational product repeat instance finding list , suggest presence hypotension : Dizziness standing , facial pallor , cold sweat 25 . ALT AST &gt; 2.0 time high upper limit normal screen 26 . Positive HBs antigen , HCV antibody , HIV antigen/antibody , serological test syphilis screen &lt; Participants renal impairment &gt; 27 . Poorly control clinically significant disease , infection , abnormality liver , nervous system , cardiovascular system , blood , lung , metabolism , gastrointestinal tract , urinary tract ; endocrine disorder ; immune disorder could affect study participation study result . 28 . Sitting systolic blood pressure &lt; 110 mmHg screening , preliminary examination , examination administration day 1 29 . ALT AST &gt; 2.0 time high upper limit normal screen 30 . Positive HBs antigen , HCV antibody , HIV antigen/antibody , serological test syphilis screen &lt; Participants hepatic impairment &gt; 31 . Have poorly control clinically significant disease , infection , abnormality kidney , nervous system , cardiovascular system , blood , metabolism , gastrointestinal tract , urinary tract ; endocrine disorder ; immune disorder could affect study participation study result . 32 . Ascites require invasive treatment 33 . Systolic blood pressure &lt; 80 mmHg screening , preliminary examination , examination administration investigational product repeat instance finding list , suggest presence hypotension : Dizziness standing , facial pallor , cold sweat 34. eGFR &lt; 60 mL/min/1.73 m2 screen 35 . At screening , positive HIV antigen/antibody positive serological test syphilis syphilis judge cure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>